Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA

Hospitalization final 90 days of life 48.3% 64.0% .0004 Hospitalization final 30 days of life 31.5% 61.5%